BDX - Medical Device Maker Becton Dickinson's Q1 Earnings: Here's Why This Analyst Is Bullish On Long-Term Prospects | Benzinga
Becton, Dickinson, and Company (NYSE:BDX) posted first-quarter 2024 adjusted EPS of $2.68, beating the consensus of $2.40.
BD reported sales of $4.71 billion, up 2.6% Y/Y (+1.6 on constant currency), slightly below the consensus of $4.73 billion.
The company’s medical segment reported a 3.5% growth to $2.23 billion, and its interventional business grew by 5.2% to $1.19 billion. Life sciences revenue declined 1% to $1.29 billion.
Guidance: BD expects fiscal year 2024 revenues of approximately $20.2 billion-$20.4 billion versus the consensus of $20.2 billion and prior guidance of $20.1 billion-$20.3 billion.
The ...